Pim Kinases as Therapeutic Targets in Early Rheumatoid Arthritis

Abstract

Objective As well as being an established oncoprotein and therapeutic target in cancer, proviral integration site for Moloney murine leukemia virus 1 (Pim‐1) is implicated in human autoimmunity. This study was undertaken to investigate Pim‐1 and its family members as potential therapeutic targets in early rheumatoid arthritis (RA). Methods A flow cytometry assay for PIM1 transcript measurement in peripheral blood mononuclear cells from patients with early arthritis was validated and applied as a biomarker of Pim‐1 activity at the cellular level. Synovial protein expression was similarly determined by multiplex immunofluorescence in tissue samples from untreated RA patients and non‐RA disease controls. Functional consequences of Pim kinase family manipulation in freshly isolated CD4+ T cells from these individuals were ascertained, along with the impact of Pim inhibition on mice with collagen‐induced arthritis (CIA). Results The percentage of circulating CD4+ T cells positive for PIM1 transcript by flow cytometry proved a faithful surrogate for gene expression and was significantly higher in patients with early RA than in those with other diseases. Pim‐1 protein levels were similarly up‐regulated in synovial CD4+ T cells from patients with early RA. Ex vivo, exposure of T cell receptor–stimulated early RA CD4+ T cells to Pim kinase inhibitors restrained their activation and proliferative capacity. Diminished production of proinflammatory cytokines (interferon‐γ and interleukin‐17) and an expanded CD25highFoxP3+ Treg cell fraction were also observed in exposed versus unexposed cells. Finally, administration of Pim inhibitors robustly limited arthritis progression and cartilage destruction in CIA. Conclusion Our findings indicate that Pim kinases are plausible therapeutic targets in a readily identifiable subgroup of patients with early RA. Repurposing of Pim inhibitors for this disease should be considered.

Bifidobacterium longum subsp. infantis B6MNI Alleviates Collagen-Induced Arthritis in Rats via Regulating 5-HIAA and Pim-1/JAK/STAT3 Inflammation Pathways

“…Additionally, Pim-1 has been reported as a therapeutic target for early RA. 26 In early RA patients, the level of Pim-1 is significantly higher than that of normal individuals. 27 We found that 5-HIAA can bind to the active pocket of Pim-1 that may indicate that 5-HIAA can inhibit the amplification of proinflammatory cytokines by binding with Pim-1, thus limiting the progression of arthritis and cartilage destruction.…”

A novel IRAK4/PIM1 inhibitor ameliorates rheumatoid arthritis and lymphoid malignancy by blocking the TLR/MYD88-mediated NF-κB pathway

“…Synovial tissues and fibroblasts in RA patients show upregulated PIM1 expression, and pan-PIM inhibitor alleviated arthritis progression and cartilage destruction in an RA mouse model 79 , 80 . These reports suggest that there are shared pathogenic mechanisms between ABC-DLBCL and RA, which are possibly cured by KIC-0101.…”

An overview of pim kinase as a target in multiple myeloma

“…pim‐1 kinase supports memory fitness in CD8 + T cells by supporting the expression of Eomes, and thus the memory of CD8 + T cells 102 . Pim kinase is expressed more in Th1 than Th2 cells, 103 whereas pim‐1 was reported to be strongly upregulated in CD4 + cells from human cord blood differentiated toward Th1 cells, but not in cells toward Th2 cells 104 . However, pim‐2 kinase can phosphorylate Foxp3, which leads to reduced suppressive functions of Treg cells 105 .…”